Brand new medicine for diabetes - first approved in Japan, now available in India for the first time.
For more information on generics from Lupin click here
Information about Twymeeg (Imeglimin)
Twymeeg (Imeglimin) is an oral medication developed for the treatment of type 2 diabetes. It is the first in a new class of oral drugs called "glimin," designed to address multiple aspects of type 2 diabetes, including improving insulin sensitivity and reducing blood sugar production in the liver. It is typically used in combination with other diabetic medications to improve glycemic control.
Product Highlights
- Twymeeg is indicated for the treatment of type 2 diabetes in adults, particularly for improving glycemic control alongside diet and exercise.
- It can be prescribed either as a single treatment or alongside other diabetes medications.
Key Ingredient
Imeglimin: The active ingredient in Twymeeg, imeglimin, is a novel oral antidiabetic medication that targets multiple pathways involved in glucose regulation. It acts on the pancreas, liver, and muscles to improve insulin sensitivity and reduce blood sugar levels.
Key Benefits
- Twymeeg effectively helps lower blood sugar levels in patients with type 2 diabetes, which can help prevent complications related to poorly controlled diabetes.
- It works by improving insulin secretion, enhancing insulin sensitivity, and reducing liver glucose production.
- The medication is taken by mouth, offering an easier alternative to injectables for managing diabetes.
- Unlike some other diabetes medications, imeglimin has a lower risk of causing low blood sugar when used alone, although the risk may increase when combined with other drugs that lower blood sugar.
Direction of Use
- Twymeeg is typically prescribed as an oral tablet, with a usual dose of 500 mg taken twice daily with meals.
- Patients should follow their doctor’s prescribed dosage and treatment plan, and it's often used in combination with other antidiabetic medications such as metformin.
- It is recommended to be taken with food to reduce gastrointestinal side effects.
Safety Concerns
- Common side effects may include nausea, diarrhea, or abdominal discomfort. These are typically mild and improve over time.
- Caution is advised when using Twymeeg in patients with impaired kidney function. Kidney function should be monitored, as the medication may not be suitable for those with severe kidney disease.
- While imeglimin itself has a lower risk of causing hypoglycemia, if combined with other blood-sugar-lowering medications (such as sulfonylureas or insulin), the risk of hypoglycemia may increase.
- As with any new medication, ongoing monitoring is recommended to observe long-term effects.
Avoid Twymeeg (Imeglimin) If
- Twymeeg is contraindicated in individuals with significant renal dysfunction, as it may accumulate and lead to adverse effects.
- As with any medication, an allergic reaction to imeglimin can cause serious health issues, and it should be avoided in such cases.
- There is limited information about the use of imeglimin during pregnancy or breastfeeding, so it should only be used if clearly necessary and prescribed by a healthcare provider.
